Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
NCT00790192 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2008
- Completion date
- July 31, 2010
- Enrollment
- 488 (actual)
- Sites
- 65
Conditions
As the registry lists them; a condition with its own page is linked.